SIRT3 inhibits cell proliferation in human gastric cancer through down-regulation of Notch-1

International Journal of Clinical and Experimental Medicine

Volumn 8, Issue 4, 2015, Pages 5263-5271

  Wang, Liang ^a,b   Wang, Wei Yan ^c   Cao, Li Ping ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b ZHEJIANG CANCER HOSPITAL   (China)

^c ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Cell proliferation; Gastric cancer; Notch 1; SIRT3

Indexed keywords

NOTCH1 RECEPTOR; SIRTUIN 3;

ARTICLE; CELL CULTURE; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PLASMID; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; RECEPTOR DOWN REGULATION; STOMACH CANCER; STOMACH EPITHELIUM; WESTERN BLOTTING;

EID: 84935882285     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64: 9-29.
2. Crew KD, Neugut AI. Epidemiology of upper gastrointestinal malignancies. Semin Oncol 2004; 31: 450-464.
3. Villanueva MT. Therapeutics: Gastric cancer gets a red carpet treatment. Nat Rev Cancer 2014; 14.
4. Kim KH, Kim MC, Jung GJ, Jang JS, Choi SR. Endoscopic treatment and risk factors of postoperative anastomotic bleeding after gastrectomy for gastric cancer. Int J Surg 2012; 10: 593-597.
5. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2013; 24 Suppl 6: vi57-63.
6. Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO. Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 2011; 25: 1517-1524.
7. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, Katai H, Sano T, Imamura H, Sasako M. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res 2012; 18: 5992-6000.
8. Liakakos T, Fatourou E, Ziogas D, Lykoudis E, Roukos DH. Targeting VEGF, EGFR, and other interacting pathways for gastric cancer-promises and reality. Ann Surg Oncol 2008; 15: 2981-2982, 2983-2985.
9. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460: 587-591.
10. Mostoslavsky R, Chua KF, Lombard DB, Pang WW, Fischer MR, Gellon L, Liu P, Mostoslavsky G, Franco S, Frendewey D, Auerbach W, Valenzuela D, Karow M, Hottiger MO, Hursting S, Barrett JC, Guarente L, Mulligan R, Demple B, Yancopoulos GD, Alt FW. Genomic instability and aging-like phenotype in the absence of mammalian SIRT6. Cell 2006; 124: 315-329.
11. Bosch-Presegue L, Vaquero A. The dual role of sirtuins in cancer. Genes Cancer 2011; 2: 648-662.
12. Carafa V, Nebbioso A, Altucci L. Sirtuins and disease: the road ahead. Front Pharmacol 2012; 3: 4.
13. Baur JA, Ungvari Z, Minor RK, Le Couteur DG, de Cabo R. Are sirtuins viable targets for improving healthspan and lifespan? Nat Rev Drug Discov 2012; 11: 443-461.
14. Hall JA, Dominy JE, Lee Y, Puigserver P. The sirtuin family’s role in aging and age-associated pathologies. J Clin Invest 2013; 123: 973-979.
15. Finley LW, Carracedo A, Lee J, Souza A, Egia A, Zhang J, Teruya-Feldstein J, Moreira PI, Cardoso SM, Clish CB, Pandolfi PP, Haigis MC. SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization. Cancer Cell 2011; 19: 416-428.
16. Zhang CZ, Liu L, Cai M, Pan Y, Fu J, Cao Y, Yun J. Low SIRT3 expression correlates with poor differentiation and unfavorable prognosis in primary hepatocellular carcinoma. PLoS One 2012; 7: e51703.
17. Zhang YY, Zhou LM. Sirt3 inhibits hepatocellular carcinoma cell growth through reducing Mdm2-mediated p53 degradation. Biochem Biophys Res Commun 2012; 423: 26-31.
18. Lai CC, Lin PM, Lin SF, Hsu CH, Lin HC, Hu ML, Hsu CM, Yang MY. Altered expression of SIRT gene family in head and neck squamous cell carcinoma. Tumour Biol 2013; 34: 1847-1854.
19. Bruzzone S, Parenti MD, Grozio A, Ballestrero A, Bauer I, Del RA, Nencioni A. Rejuvenating sirtuins: the rise of a new family of cancer drug targets. Curr Pharm Des 2013; 19: 614-623.
20. McGuinness D, McGuinness DH, McCaul JA, Shiels PG. Sirtuins, bioageing, and cancer. J Aging Res 2011; 2011: 235754.
21. Sundaresan NR, Samant SA, Pillai VB, Rajamohan SB, Gupta MP. SIRT3 is a stress-responsive deacetylase in cardiomyocytes that protects cells from stress-mediated cell death by deacetylation of Ku70. Mol Cell Biol 2008; 28: 6384-6401.
22. Xiao K, Jiang J, Wang W, Cao S, Zhu L, Zeng H, Ouyang R, Zhou R, Chen P. Sirt3 is a tumor suppressor in lung adenocarcinoma cells. Oncol Rep 2013; 30: 1323-1328.
23. Jasper H. Sirtuins: Longevity focuses on NAD+. Nat Chem Biol 2013; 9: 666-667.
24. Martinez-Pastor B, Mostoslavsky R. Sirtuins, metabolism, and cancer. Front Pharmacol 2012; 3: 22.
25. Onyango P, Celic I, McCaffery JM, Boeke JD, Feinberg AP. SIRT3, a human SIR2 homologue, is an NAD-dependent deacetylase localized to mitochondria. Proc Natl Acad Sci U S A 2002; 99: 13653-13658.
26. Finley LW, Haigis MC. Metabolic regulation by SIRT3: implications for tumorigenesis. Trends Mol Med 2012; 18: 516-523.
27. Huang KH, Hsu CC, Fang WL, Chi CW, Sung MT, Kao HL, Li AF, Yin PH, Yang MH, Lee HC. SIRT3 expression as a biomarker for better prognosis in gastric cancer. World J Surg 2014; 38: 910-917.
28. Yang B, Fu X, Shao L, Ding Y, Zeng D. Aberrant expression of SIRT3 is conversely correlated with the progression and prognosis of human gastric cancer. Biochem Biophys Res Commun 2014; 443: 156-160.
29. Vallejo DM, Caparros E, Dominguez M. Targeting Notch signalling by the conserved miR-8/200 microRNA family in development and cancer cells. Embo J 2011; 30: 756-769.
30. Takebe N, Nguyen D, Yang SX. Targeting notch signaling pathway in cancer: clinical development advances and challenges. Pharmacol Ther 2014; 141: 140-149.
31. Li H, Mo J, Jia G, Liu C, Luan Z, Guan Y. Activation of Wnt signaling inhibits the pro-apoptotic role of Notch in gastric cancer cells. Mol Med Rep 2013; 7: 1751-1756.
32. Ayukawa T, Matsumoto K, Ishikawa HO, Ishio A, Yamakawa T, Aoyama N, Suzuki T, Matsuno K. Rescue of Notch signaling in cells incapable of GDP-L-fucose synthesis by gap junction transfer of GDP-L-fucose in Drosophila. Proc Natl Acad Sci U S A 2012; 109: 15318-15323.
33. Du X, Cheng Z, Wang YH, Guo ZH, Zhang SQ, Hu JK, Zhou ZG. Role of Notch signaling pathway in gastric cancer: a meta-analysis of the literature. World J Gastroenterol 2014; 20: 9191-9199.
34. Yao J, Qian C. Over-activated Notch-1 protects gastric carcinoma BGC-823 cells from TNFalpha-induced apoptosis. Dig Liver Dis 2009; 41: 867-874.
35. Chu D, Zhou Y, Zhang Z, Li Y, Li J, Zheng J, Zhang H, Zhao Q, Wang W, Wang R, Ji G. Notch1 expression, which is related to p65 Status, is an independent predictor of prognosis in colorectal cancer. Clin Cancer Res 2011; 17: 5686-5694.